{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:44:45Z","timestamp":1792593885116,"version":"4.5.0"},"reference-count":28,"publisher":"MyJove Corporation","issue":"223","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/68988","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T23:01:02Z","timestamp":1758927662000},"source":"Crossref","is-referenced-by-count":0,"title":["Recombineering-based Manufacturing of Engineered Viral Vectors for Research and Therapy"],"prefix":"10.3791","author":[{"given":"Annagiulia","family":"Scognamiglio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Totaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Cipriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Nicosia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Sasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guendalina","family":"Froechlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"11","key":"ref1","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.3390\/cancers12113407","type":"journal-article","article-title":"Integrity of the antiviral STING-mediated DNA sensing in tumor cells is required to sustain the immunotherapeutic efficacy of herpes simplex oncolytic virus","volume":"12","author":"Froechlich","year":"2020","unstructured":"Froechlich, G. et al. Integrity of the antiviral STING-mediated DNA sensing in tumor cells is required to sustain the immunotherapeutic efficacy of herpes simplex oncolytic virus. Cancers (Basel). 12 (11), 3407 (2020).","journal-title":"Cancers (Basel)"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"19541","DOI":"10.1038\/s41598-023-46830-5","type":"journal-article","article-title":"The common H232 STING allele shows impaired activities in DNA sensing, susceptibility to viral infection, and in monocyte cell function, while the HAQ variant possesses wild-type properties","volume":"13","author":"Froechlich","year":"2023","unstructured":"Froechlich, G. et al. The common H232 STING allele shows impaired activities in DNA sensing, susceptibility to viral infection, and in monocyte cell function, while the HAQ variant possesses wild-type properties. Sci Rep. 13 (1), 19541 (2023).","journal-title":"Sci Rep"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"101430","DOI":"10.1016\/j.smim.2020.101430","type":"journal-article","article-title":"New viral vectors for infectious diseases and cancer","volume":"50","author":"Sasso","year":"2020","unstructured":"Sasso, E. et al. New viral vectors for infectious diseases and cancer. Semin Immunol. 50 (1), 101430 (2020).","journal-title":"Semin Immunol"},{"issue":"3-4","key":"ref4","doi-asserted-by":"crossref","first-page":"107502","DOI":"10.1016\/j.biotechadv.2019.107502","type":"journal-article","article-title":"The approved gene therapy drugs worldwide: from 1998 to 2019","volume":"40","author":"Ma","year":"2020","unstructured":"Ma, C. C., Wang, Z. L., Xu, T., He, Z. Y., Wei, Y. Q. The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnol Adv. 40 (3-4), 107502 (2020).","journal-title":"Biotechnol Adv"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1038\/s41598-020-61275-w","type":"journal-article","article-title":"Replicative conditioning of herpes simplex type 1 virus by survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis","volume":"10","author":"Sasso","year":"2020","unstructured":"Sasso, E. et al. Replicative conditioning of herpes simplex type 1 virus by survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis. Sci Rep. 10 (1), 4307 (2020).","journal-title":"Sci Rep"},{"issue":"2","key":"ref6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3390\/ijms22020477","type":"journal-article","article-title":"Generation of a novel mesothelin-targeted oncolytic herpes virus and implemented strategies for manufacturing","volume":"22","author":"Froechlich","year":"2021","unstructured":"Froechlich, G. et al. Generation of a novel mesothelin-targeted oncolytic herpes virus and implemented strategies for manufacturing. Int J Mol Sci. 22 (2), 477 (2021).","journal-title":"Int J Mol Sci"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.omto.2020.10.006","type":"journal-article","article-title":"Retargeted and multi-cytokine-armed herpes virus is a potent cancer endovaccine for local and systemic anti-tumor treatment","volume":"19","author":"De Lucia","year":"2020","unstructured":"De Lucia, M. et al. Retargeted and multi-cytokine-armed herpes virus is a potent cancer endovaccine for local and systemic anti-tumor treatment. Mol Ther Oncolytics. 19 (1), 253-264 (2020).","journal-title":"Mol Ther Oncolytics"},{"issue":"1","key":"ref8","first-page":"703213","type":"journal-article","article-title":"One-step recovery of scFv clones from high-throughput sequencing-based screening of phage display libraries challenged to cells expressing native claudin-1","volume":"2015","author":"Sasso","year":"2015","unstructured":"Sasso, E. et al. One-step recovery of scFv clones from high-throughput sequencing-based screening of phage display libraries challenged to cells expressing native claudin-1. Biomed Res Int. 2015 (1), 703213 (2015).","journal-title":"Biomed Res Int"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/s41598-018-37997-3","type":"journal-article","article-title":"Revealing membrane alteration in cells overexpressing CA IX and EGFR by surface-enhanced Raman scattering","volume":"9","author":"Rusciano","year":"2019","unstructured":"Rusciano, G., Sasso, E., Capaccio, A., Zambrano, N., Sasso, A. Revealing membrane alteration in cells overexpressing CA IX and EGFR by surface-enhanced Raman scattering. Sci Rep. 9 (1), 1832 (2019).","journal-title":"Sci Rep"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","type":"journal-article","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","unstructured":"Lin, D., Shen, Y., Liang, T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 8 (1), 156 (2023).","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"200760","DOI":"10.1016\/j.omton.2024.200760","type":"journal-article","article-title":"Prime and pull of T cell responses against cancer-exogenous antigens is effective against CPI-resistant tumors","volume":"32","author":"Troise","year":"2024","unstructured":"Troise, F. et al. Prime and pull of T cell responses against cancer-exogenous antigens is effective against CPI-resistant tumors. Mol Ther Oncolytics. 32 (1), 200760 (2024).","journal-title":"Mol Ther Oncolytics"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","type":"journal-article","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","unstructured":"Shalhout, S. Z., Miller, D. M., Emerick, K. S., Kaufman, H. L. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 20 (3), 160-177 (2023).","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"ref13","first-page":"1060","type":"journal-article","article-title":"Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies","volume":"10","author":"Sasso","year":"2018","unstructured":"Sasso, E. et al. Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies. MAbs. 10 (7), 1060-1072 (2018).","journal-title":"MAbs"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3390\/cancers14010121","type":"journal-article","article-title":"Novel combinations of human immunomodulatory mAbs lacking cardiotoxic effects for therapy of TNBC","volume":"14","author":"Vetrei","year":"2021","unstructured":"Vetrei, C. et al. Novel combinations of human immunomodulatory mAbs lacking cardiotoxic effects for therapy of TNBC. Cancers (Basel). 14 (1), 121 (2021).","journal-title":"Cancers (Basel)"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3390\/cancers14051325","type":"journal-article","article-title":"High-throughput monoclonal antibody discovery from phage libraries: challenging the current preclinical pipeline to keep the pace with the increasing mAb demand","volume":"14","author":"Zambrano","year":"2022","unstructured":"Zambrano, N. et al. High-throughput monoclonal antibody discovery from phage libraries: challenging the current preclinical pipeline to keep the pace with the increasing mAb demand. Cancers (Basel). 14 (5), 1325 (2022).","journal-title":"Cancers (Basel)"},{"issue":"2","key":"ref16","doi-asserted-by":"crossref","first-page":"102531","DOI":"10.1016\/j.omtn.2025.102531","type":"journal-article","article-title":"We ARE boosting translation: AU-rich elements for enhanced therapeutic mRNA translation","volume":"36","author":"Froechlich","year":"2025","unstructured":"Froechlich, G., Sasso, E. We ARE boosting translation: AU-rich elements for enhanced therapeutic mRNA translation. Mol Ther Nucleic Acids. 36 (2), 102531 (2025).","journal-title":"Mol Ther Nucleic Acids"},{"issue":"24","key":"ref17","doi-asserted-by":"crossref","first-page":"13521","DOI":"10.3390\/ijms222413521","type":"journal-article","article-title":"Generation of a retargeted oncolytic herpes virus encoding adenosine deaminase for tumor adenosine clearance","volume":"22","author":"Gentile","year":"2021","unstructured":"Gentile, C. et al. Generation of a retargeted oncolytic herpes virus encoding adenosine deaminase for tumor adenosine clearance. Int J Mol Sci. 22 (24), 13521 (2021).","journal-title":"Int J Mol Sci"},{"issue":"9","key":"ref18","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/s41417-024-00790-8","type":"journal-article","article-title":"Integrating system biology and intratumor gene therapy by trans-complementing the appropriate co-stimulatory molecule as payload in oncolytic herpes virus","volume":"31","author":"Finizio","year":"2024","unstructured":"Finizio, A. et al. Integrating system biology and intratumor gene therapy by trans-complementing the appropriate co-stimulatory molecule as payload in oncolytic herpes virus. Cancer Gene Ther. 31 (9), 1335-1343 (2024).","journal-title":"Cancer Gene Ther"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3390\/cancers15041297","type":"journal-article","article-title":"Systems biology approaches for the improvement of oncolytic virus-based immunotherapies","volume":"15","author":"Tripodi","year":"2023","unstructured":"Tripodi, L. et al. Systems biology approaches for the improvement of oncolytic virus-based immunotherapies. Cancers (Basel). 15 (4), 1297 (2023).","journal-title":"Cancers (Basel)"},{"issue":"5","key":"ref20","doi-asserted-by":"crossref","first-page":"e008025","DOI":"10.1136\/jitc-2023-008025","type":"journal-article","article-title":"Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy","volume":"12","author":"Wang","year":"2024","unstructured":"Wang, H. et al. Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? J Immunother Cancer. 12 (5), e008025 (2024).","journal-title":"J Immunother Cancer"},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"1156714","DOI":"10.3389\/fimmu.2023.1156714","type":"journal-article","article-title":"Adenovirus encoded adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve adenovirus based vaccines against infectious diseases and cancer","volume":"14","author":"D'Alise","year":"2023","unstructured":"D'Alise, A. M. et al. Adenovirus encoded adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve adenovirus based vaccines against infectious diseases and cancer. Front Immunol. 14 (1), 1156714 (2023).","journal-title":"Front Immunol"},{"issue":"6","key":"ref22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1566523213666131125095046","type":"journal-article","article-title":"Adenovirus vectors for gene therapy, vaccination and cancer gene therapy","volume":"13","author":"Wold","year":"2013","unstructured":"Wold, W. S., Toth, K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther. 13 (6), 421-433 (2013).","journal-title":"Curr Gene Ther"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-1-4939-0428-0_5","type":"journal-article","article-title":"Engineering HSV-1 vectors for gene therapy","volume":"1144","author":"Goins","year":"2014","unstructured":"Goins, W. F., Huang, S., Cohen, J. B., Glorioso, J. C. Engineering HSV-1 vectors for gene therapy. Methods Mol Biol. 1144 (1), 63-79 (2014).","journal-title":"Methods Mol Biol"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"142230","DOI":"10.1016\/j.ijbiomac.2025.142230","type":"journal-article","article-title":"Peptide nucleic acid-mediated circularization of target RNA as tool to inhibit translation","volume":"308","author":"De Chiara","year":"2025","unstructured":"De Chiara, A. et al. Peptide nucleic acid-mediated circularization of target RNA as tool to inhibit translation. Int J Biol Macromol. 308 (1), 142230 (2025).","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"704999","DOI":"10.3389\/fonc.2021.704999","type":"journal-article","article-title":"The application of CRISPR\/Cas9 technology for cancer immunotherapy: current status and problems","volume":"11","author":"Wang","year":"2022","unstructured":"Wang, L., Chen, Y., Liu, X., Li, Z., Dai, X. The application of CRISPR\/Cas9 technology for cancer immunotherapy: current status and problems. Front Oncol. 11 (1), 704999 (2022).","journal-title":"Front Oncol"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/nprot.2008.227","type":"journal-article","article-title":"Recombineering: a homologous recombination-based method of genetic engineering","volume":"4","author":"Sharan","year":"2009","unstructured":"Sharan, S. K., Thomason, L. C., Kuznetsov, S. G., Court, D. L. Recombineering: a homologous recombination-based method of genetic engineering. Nat Protoc. 4 (2), 206-223 (2009).","journal-title":"Nat Protoc"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1093\/nar\/gni035","type":"journal-article","article-title":"Simple and highly efficient BAC recombineering using galK selection","volume":"33","author":"Warming","year":"2005","unstructured":"Warming, S., Costantino, N., Court, D. L., Jenkins, N. A., Copeland, N. G. Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res. 33 (4), e36 (2005).","journal-title":"Nucleic Acids Res"},{"issue":"17","key":"ref28","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.3390\/ijms21176370","type":"journal-article","article-title":"High-throughput cloning and characterization of emerging adenovirus types 70, 73, 74, and 75","volume":"21","author":"Zhang","year":"2020","unstructured":"Zhang, W. et al. High-throughput cloning and characterization of emerging adenovirus types 70, 73, 74, and 75. Int J Mol Sci. 21 (17), 6370 (2020).","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/app.jove.com\/t\/68988\/recombineering-based-manufacturing-engineered-viral-vectors-for","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:28:17Z","timestamp":1792592897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jove.com\/t\/68988\/recombineering-based-manufacturing-engineered-viral-vectors-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":28,"journal-issue":{"issue":"223","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3791\/68988","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]}}}